Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Liothyronine (T3) and Nandrolone Interaction: Avoid | Peptide Database

Compound Profiles Liothyronine (T3) Thyroid Hormone | Metabolic Optimization Liothyronine enters target cells via monocarboxylate transporter 8 (MCT8) and other thyroid hormone transporters, then binds to nuclear thyroid hormone receptors (primarily TR-beta in

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Liothyronine (T3)

Thyroid Hormone | Metabolic Optimization

Liothyronine enters target cells via monocarboxylate transporter 8 (MCT8) and other thyroid hormone transporters, then binds to nuclear thyroid hormone receptors (primarily TR-beta in metabolic tissues and TR-alpha in cardiac tissue). The T3-receptor complex forms heterodimers with retinoid X receptors (RXR) and binds to thyroid hormone response elements (TREs) on DNA, directly modulating gene transcription.

Nandrolone

Anabolic-Androgenic Steroid | Joint & Collagen Support

Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Liothyronine (T3) with Nandrolone?

Combining Liothyronine (T3) with Nandrolone is not recommended. Both Liothyronine (T3) and Nandrolone carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.

Is Liothyronine (T3) and Nandrolone safe together?

This combination carries significant risk. Both Liothyronine (T3) and Nandrolone carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended. Consult a healthcare professional before combining.

What are the interactions between Liothyronine (T3) and Nandrolone?

Both Liothyronine (T3) and Nandrolone carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended. This assessment has 70% confidence and is inferred from pharmacological mechanism analysis.

How should I time Liothyronine (T3) and Nandrolone?

Liothyronine (T3) has a half-life of ~1 day and Nandrolone has a half-life of ~6-12 days (decanoate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Chonluten — share findings, ask questions, and learn from real experiences Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD. Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

Source: peptide-db.com ↗

Research Indications

GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction. Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%). Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits. HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%. 48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide. Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials. Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Sublingual administration is the most common route for 9-Me-BC in the nootropic community. The compound is typically supplied as a powder or in capsule form, with sublingual dosing preferred for improved bioavailability by bypassing first-pass hepatic metabolism. The powder is held under the tongue for 1-2 minutes before swallowing. Dosing should occur exclusively in the morning to minimize any risk of insomnia from dopaminergic stimulation, and strict sun avoidance must be maintained throughout the entire period of use. Standard Nootropic / Dopamine Restoration 5-15 mg Once daily in the morning Sublingual

Source: peptide-db.com ↗
Side effects

Common Side Effects

Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression) Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride) Decreased ejaculate volume (reported in 1-2%) Gynecomastia or breast tenderness (reported in approximately 1-2%)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides